Becton, Dickinson and Company rallied both interest and adjustment in the market, as evidenced by multiple institutional asset management selling and acquiring shares in the company. Amid concerns regarding heavy usage of
debt, some believe the company still garners attention due to its
Value Stock profile. Regarding
quarter earnings, despite topping Q3, the company missed revenue goals, and lowered than expected 2024 Guidance prompted a drop in share pricing. However, BDX subsequently reported surpassing Q2 earnings and revenue estimates. Despite negatives, the value of BDX remains strong due to continued
product demand. BDX was named among
Fortune's Most Innovative companies, and made
2025 commitments hinting towards continued growth. Major shares are sold by EVP & President of Medical Michael Garrison. BDX continually outperformed competitors in the market, even on sluggish days. The company has also been under the spotlight for potentially transformative
FDA 510(k) Clearance for a Fingertip Blood Collection Device. Other key highlights included collaborations to standardize single-cell
multiomics experiments using robotics, and the initiation of an international study for
peripheral arterial disease treatment options.
Becton Dickinson and BDX News Analytics from Mon, 24 Jul 2023 07:00:00 GMT to Sun, 26 May 2024 11:53:28 GMT -
Rating 4
- Innovation 6
- Information 7
- Rumor -3
